CIREX | CVLCX | CIREX / CVLCX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 23 years | 28 years | - |
Gain YTD | 10.752 | 20.158 | 53% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 250 | 2500 | 10% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 108B | 260M | 41,538% |
Annual Yield % from dividends | 3.02 | 0.21 | 1,452% |
Returns for 1 year | 18.42 | 24.43 | 75% |
Returns for 3 years | 14.22 | -0.87 | -1,630% |
Returns for 5 years | 37.59 | 42.23 | 89% |
Returns for 10 years | 63.45 | 10.38 | 611% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
DGEYX | 20.74 | 0.09 | +0.44% |
BNY Mellon Global Emerging Mkts - Y | |||
PGTIX | 18.68 | 0.04 | +0.21% |
T. Rowe Price Global Technology I | |||
VAGVX | 27.75 | -0.10 | -0.36% |
Vanguard Advice Select Global Value Adml | |||
MSCUX | 12.20 | -0.08 | -0.65% |
Morgan Stanley American Resilience A | |||
RYOAX | 66.30 | -0.54 | -0.81% |
Rydex Biotechnology H |